-
First treatment to target heart condition set to benefit thousands as NICE draft guidance approves NHS use
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.
-
145,000 people in England to have further treatment choice for preventing migraine attacks.
NICE has for the first time recommended an oral treatment for preventing migraines.
-
NICE welcomes life sciences review recommendations
NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.
-
Testing could help prevent further strokes in people with gene variant
People who have had an ischaemic stroke or transient ischaemic attack (TIA) should have a genetic test to find out whether they can be treated with a drug which reduces the risk of further strokes, NICE has said.
-
NICE draft guidance recommends new treatment for chronic heart failure
Up to 150,000 people in England with a type of chronic heart failure are set to benefit from a new treatment following its approval by NICE.
-
Nine treatment options to be made available for adults with depression or an anxiety disorder
Six digitally enabled therapies for adults with anxiety disorders and three for adults with depression have been recommended for use in the NHS while further data is gathered, NICE has said.
-
Hundreds of children with type 2 diabetes to be offered choice of two life changing technologies
Hundreds of children with type 2 diabetes who currently manage their condition with the ‘burdensome’, ‘tiring’, and ‘stressful’ task of finger prick testing several times a day could be offered a choice between two ‘life changing’ technologies to virtually automate the process, NICE has said.
-
Two new personalised immunotherapy treatments for aggressive forms of blood cancer recommended for the Cancer Drugs Fund
NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer
-
NICE collaborates with international partner agencies to streamline the confidential marking process
NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review have today (24 April 2023) announced they are changing the way confidential information about health technologies is handled to streamline processes and increase transparency.